<DOC>
	<DOC>NCT00676819</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to investigate if the pharmacodynamic / pharmacokinetic properties of insulin aspart and human soluble insulin are different in elderly (65 years of age or older) with type 2 diabetes.</brief_summary>
	<brief_title>Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Insulin in Elderly People With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>Type 2 diabetes Duration of diabetes for at least 12 months Current treatment with human insulin or insulin analogues for at least 6 months BMI equal to or below 35 kg/m2 HbA1c equal to or greater than 10.0 % No clinically significant cardiovascular event as judged by the Investigator within the last 6 months prior to the study History of any illness that, in the opinion of the Investigator might confound the results of the study or pose additional risk in administering the trial products to the subject Current treatment with systemic corticosteroids Any positive reaction of drug of abuse or alcohol screen Cardiac problems defined as: decompensated heart failure and/or angina pectoris Uncontrolled treated/untreated hypertension as judged by the Investigator or blood pressure &gt; 180 mm Hg systolic and/or &gt; 110 mm Hg diastolic Known or suspected allergy to trial product or related products Blood donation of more than 500 ml within the last 12 weeks The receipt of any investigational drug within 4 weeks prior to this trial</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>